600 results about "Herpes virus" patented technology

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

The invention discloses an application of lactic acid (Lactate) in prevention and treatment of infection of CyHV-2 (Cyprinid Herpesvirus, CyHV-2), SVCV (Spring Viraemia of Carp Virus) and GCRV (Grass Carp Reovirus), a result of a cell line infection model shows that the lactic acid has a significant protection effect on cells infected by CyHV-2, SVCV and GCRV, and the lactic acid has a significant protection effect on cells infected by CyHV-2, SVCV and GCRV. Furthermore, a molecular biology experiment result shows that the transcription level of the virus related genes treated by lactic acid is obviously inhibited. Therefore, the lactic acid can be used as a medicine or an additive for preventing and treating CyHV-2, SVCV and GCRV infection, and has the advantages of low dosage and good protection effect.

The invention discloses a reagent and a method for detecting berberine-resistant viruses. The reagent provided by the invention comprises an antibody or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR1-3 and / or a light chain complementarity determining region LCDR1-3, the heavy chain complementarity determining region HCDR1-3 has a sequence as shown in SEQ ID NO.5-7, and the light chain complementarity determining region LCDR1-3 has a sequence as shown in SEQ ID NO.8-10. The reagent can be used for detecting the berberine-resistant herpes simplex virus type 1, so that the treatment effect can be evaluated in advance before berberine is applied for treatment.

The invention belongs to the technical field of biology, and discloses a recombinant turkey herpesvirus co-expressing an avian influenza H9 gene and an avian adenovirus 4 type Fiber-2 gene, the H9 gene containing a promoter and a terminator is inserted between an HVT053 site and an HVT054 site of the turkey herpesvirus, the Fiber-2 gene containing a promoter and a terminator is inserted between an HVT087 site and an HVT088 site of the turkey herpesvirus, and the recombinant turkey herpesvirus co-expressing the avian influenza H9 gene and the avian adenovirus 4 type Fiber-2 gene is obtained. The recombinant virus is obtained. The recombinant turkey herpesvirus can stably co-express the H9N2 subtype avian influenza virus H9 protein and the fowl adenovirus 4 type Fiber-2 protein, has very excellent immune performance, and effectively improves the immune effect of the recombinant virus of the traditional fowl adenovirus Fiber-2 gene; compared with the recombinant herpesvirus of turkey which singly expresses any one of the H9N2 subtype avian influenza virus H9 protein and the fowl adenovirus 4 type Fiber-2 protein, the recombinant herpesvirus of turkey has the advantage that the performance of the recombinant herpesvirus of turkey is not weakened. Meanwhile, the invention also provides application and a vaccine of the recombinant herpesvirus of turkeys.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

The invention provides a kit and a method for simultaneously detecting 11 pathogens of a urogenital system and application, and belongs to the field of molecular biology. The primer group is used for detecting urogenital tract pathogens, and the urogenital tract pathogens comprise ureaplasma urealyticum (UU), chlamydia trachomatis (CT), mycoplasma genitalium (MG), ureaplasma parvum (UP), mycoplasma hominis (MH), adenovirus (ADV), trichomonas vaginalis (TV), herpes simplex virus type I (HSV-I), herpes simplex virus type II (HSV-II), haemophilus influenzae (HI) and neisseria gonorrhoeae (NG). The primer group is used for multi-joint detection of non-gonococcal urethritis related pathogens, has high specificity and sensitivity, is adaptive to non-invasive urine specimens, and supports home self-sampling. The kit is used for clinical diagnosis and can quickly judge pathogen types. Precise medication is performed based on a detection result, the healing time of a patient is shortened, the burden of a doctor is relieved, and meanwhile the pathogen transmission risk is reduced.

The present invention relates to methods and compositions for treating and / or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. In particular, provided are long-acting injectable depot pharmaceutical compositions comprising Compound 1 or a pharmaceutically acceptable salt thereof; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament and for the treatment of diseases or disorders caused by, or associated with, herpes virus.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The invention discloses pyridone endoperoxide with antibacterial and antiviral activity and application thereof, and belongs to the fields of organic compound synthesis and medical technology, food engineering and the like. The invention proves that the series of endoperoxides can effectively kill pathogenic bacteria, fungi and viruses, including propionibacterium acnes, escherichia coli, staphylococcus aureus, candida albicans, human papilloma viruses, herpes simplex viruses and the like. The internal peroxide designed by the invention has the capability of treating skin diseases, is expected to be developed into a first-line medicine for treating skin diseases caused by pathogen invasion, and mainly relates to bacterial skin diseases, fungal skin diseases and viral skin diseases caused by pathogen infection. Meanwhile, the series of endoperoxides can be used for treating oral infection, periodontitis, infection of shoulder and other joint operations, and bacterial infection such as pressure sores. In addition, the peroxides in the series can also be used in the fields of food preservation, disinfectant preparation and the like.

The invention discloses an HSV-1 replication-deficient recombinant virus vector and an application of the HSV-1 replication-deficient recombinant virus vector. Specifically, the method comprises the following steps: performing gene editing on a specific genome segment in an HSV-1 genome to obtain an HSV-1 replication-defective recombinant virus vector; wherein compared with the existing HSV-1 replication-deficient recombinant virus vector, the HSV-1 replication-deficient recombinant virus vector can express an exogenous gene more efficiently, and the HSV-1 replication-deficient recombinant virus vector, as an excellent delivery vector, can effectively deliver the exogenous gene into the body of a subject to achieve a treatment effect.

The invention relates to a novel crystalline form of a helicase-primase inhibitor compound, as well as to pharmaceutical compositions comprising the same, methods for its production, the use of the crystalline form in a medicament and for the treatment of herpes virus infections.

The invention relates to a novel crystalline form of a helicase-primase inhibitor compound, as well as to pharmaceutical compositions comprising the same, methods for its production, the use of the crystalline form in a medicament and for the treatment of herpes virus infections.

The invention discloses a novel helper plasmid for producing a recombinant adeno-associated virus as well as a construction method and application of the novel helper plasmid. The novel helper plasmid is constructed by inserting a UL12 element of an I-type herpes simplex virus HSV-1 and an NS2 element of a human bola virus HBoV into a basic pHelper plasmid, the constructed novel helper plasmid UL12-NS2-pHelper can remarkably improve the titer of rAAV produced by HEK293 cells, the proportion of solid rAAV is increased, immunoreaction and toxicity caused by empty capsid can be reduced, and the helper plasmid can be used for preparing the rAAV. The treatment dosage is reduced, and the curative effect and safety are improved.

The invention relates to the technical field related to immunological detection, in particular to a mouse anti-porcine herpesvirus type 1 gE monoclonal antibody as well as an immunogen and application of the mouse anti-porcine herpesvirus type 1 gE monoclonal antibody. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: GFSLSTSGMG, IVWGSETGRVTISRDNSK and VRYYDGDDD, and the amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: KSSQSLLYSDGKTFLN, LGSNRAS and SSLPHED. The monoclonal antibody can be specifically combined with gE proteins of all subtypes of the porcine herpesvirus type 1, and a porcine herpesvirus type 1 detection kit prepared from the monoclonal antibody has the advantages of high sensitivity, strong specificity, wide detection range, short detection time and the like.

Provided herein are methods and compositions for treating and / or inhibiting the development or progression of conditions caused by, or associated with, Herpes Simplex Virus (HSV) infection. In particular, provided are compositions comprising lopinavir alone, or lopinavir and ritonavir, methods for their manufacture; and the use of said pharmaceutical compositions as a medicament. In particular, pharmaceutical compositions are provided for use in treating and / or inhibiting the progression of HSV related conditions.

The present invention discloses a biomarker for predicting the efficacy of oncolytic virus in treating malignant tumors and its application. The biomarker includes SH3BP2, the oncolytic virus is oncolytic herpes simplex virus, and the malignant tumor is glioma. Before treating malignant glioma with oncolytic virus, the expression level of SH3BP2 in tumor tissues before treatment is detected to predict the therapeutic effect of oncolytic virus on malignant glioma.

The invention relates to the field of medicinal chemistry, and particularly discloses purine compounds as well as a preparation method and application thereof. The purine compound provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof: # imgabs0 #. The purine compound disclosed by the invention is designed based on a novel purine skeleton structure, and the anti-herpes simplex virus type 1 (HSV-1) activity of the purine compound is verified through an in-vitro antiviral experiment. Experimental data show that the HSV-1 median inhibitory concentration (EC50) of the series of compounds to HSV-1 is obviously superior to that of a clinical first-line drug acyclovir, and the series of compounds show better virus inhibition efficiency on the premise of keeping a similar selectivity index (SI = CC50 / EC50). The technical scheme breaks through the molecular framework limitation of the existing anti-HSV-1 drugs (such as acyclovir, famciclovir and the like), and has good clinical transformation value.

The present disclosure relates to compositions and methods for treating or preventing neonatal herpes simplex virus (HSV) infection and / or the neurological and / or non-neurological sequelae thereof.

The invention discloses a cat kidney suspension culture cell line suitable for serum-free suspension culture and application of the cat kidney suspension culture cell line. The name of the cell line is F81-B4, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.46350. After 50 generations of continuous subculture, the cells still can maintain the original proliferation level and cellular morphology, the cell number can reach 9.0 * 10 < 6 > / mL after the cells are subcultured at the density of 1.0 * 10 < 6 > / mL for three days, the multiplication time is 22-26 hours, and the cell proliferation speed is equivalent to that in a shake flask when the cells are amplified to a 10L bioreactor for culture. The cell line is highly susceptible to feline parvovirus, feline calicivirus, feline herpes virus, canine parvovirus and canine distemper virus, the virus content of a virus solution harvested 72 h after FPV virus inoculation can reach 107.5 TCID50 / mL, the virus content of a virus solution harvested 24 h after FCV virus inoculation can reach 1010.8 TCID50 / mL, the virus content of a virus solution harvested 48 h after FHV-1 virus inoculation can reach 107.5 TCID50 / mL, compared with an existing F81 adherent cell production process, the production process has the advantages that the production efficiency is high, and the production cost is low. The method has the characteristics of rapid lesion, short virus collection time and high titer. The cell matrix is an ideal cell matrix which can be used for culturing the three viruses.

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant oncolytic herpesvirus and application thereof. In order to solve the problems of insufficient replication efficiency, limited immune activation and the like of the existing oncolytic herpesvirus, the invention provides a recombinant oncolytic herpesvirus which contains a coding neurotoxic factor regulated by a tumor specific promoter or a gene related to replication and a gene segment for coding an immunomodulatory factor. Experiments prove that the recombinant oncolytic herpesvirus prepared by the invention has multiple advantages of high replication efficiency, strong tumor targeting, remarkable treatment effect on various tumors, high safety and the like, provides a brand new drug development thought and treatment choice for the field of tumor immunotherapy, and has important clinical application value and market prospect.

The present invention relates to an antimicrobial and healing formulation for skin, designed to effectively target and treat skin conditions such as acne caused by Cutibacterium acnes, cold sore lesions due to the herpes simplex virus, and superficial wounds. This unique formulation combines antimicrobial agents, plant extracts and essential oils in specific proportions in order to exert a synergistic action, enhancing their individual efficacy in the treatment of skin conditions and promoting skin healing. The innovative formulation composed of niaouli (Melaleuca viridiflora) essential oil and tea tree (Melaleuca alternifolia) essential oil, chlorhexidine digluconate, Hamamelis virginiana extract, panthenol, glycerol, and propylene glycol. Each ingredient has been selected for its proven pharmacological properties and its synergistic potential. The formulation works in concert to reduce microbial load, alleviate inflammation, and accelerate skin healing, while providing a gentle and effective application.

The invention discloses a peristaltic pump for herpes zoster virus liquid ultrafiltration and an ultrafiltration process, and relates to the technical field of biological pharmacy, the peristaltic pump comprises an energy-saving motor, a main wheel, a substitute wheel, a vertical seat and a pump pipe, an extension cylinder is fixedly arranged on the rear side face of the vertical seat, and the energy-saving motor is fixedly connected to the side face of the extension cylinder. A group of main wheels and a group of substitute wheels are arranged in the peristaltic pump shell, a switching assembly is arranged in the peristaltic pump shell, the peristaltic pump can creep when the main wheels are in a normal state, and when the main wheels of the peristaltic pump are damaged, a user can quickly move the main wheels away from the creep station through the switching assembly, so that the peristaltic pump is convenient to use. And then the secondary wheel is arranged at a peristaltic station, so that long-time shutdown waiting is avoided, the working continuity and the production efficiency of equipment are effectively improved, the peristaltic pump can be ensured to recover to work as soon as possible when a fault occurs, the dependence on high-skill workers is also reduced, and the maintenance work is simpler and more efficient.

The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.

The invention belongs to the technical field of fish genetic breeding, and particularly relates to a creation method of an anti-herpes virus double-triploid carp and crucian carp cloning line with a growth advantage. The method comprises the following steps: breeding a gynogenesis double-triploid prussian carp female parent and a sexual reproduction double-diploid prussian carp male parent to obtain a filial generation G1, screening male fish from the filial generation G1, and hybridizing the male fish with double-diploid Yellow River carp female fish to obtain a double-triploid prussian carp filial generation G2; female fish in the filial generation G2 is used as a female parent, natural gynogenesis is carried out on the female parent and the male parent Xinguo red carp, a filial generation G3 is obtained, and the G3 is an anti-herpes virus double-triploid carp and crucian carp cloning line. A brand-new breeding route for creating the bitriploid carp and crucian carp cloning line is established, genomes of Yellow River carps, prussian carps and crucian carps are integrated and reconstructed, so that the bitriploid carp and crucian carps form obvious heterosis in blister disease virus resistance and growth speed, and the bitriploid carp and crucian carp cloning line has a wide application prospect.

The invention belongs to the field of biological medicine, and particularly relates to an artificially synthesized polypeptide P2 and application thereof in resisting herpes virus infection. According to the invention, a polypeptide P2 of key amino acid residues (77N, 80I, 82N, 84N, 85N and 129F) combined with virus glycoprotein gD in a specific targeting host cell surface receptor Nectin-1 is designed and obtained through an RFdiffusion algorithm; the polypeptide P2 can significantly inhibit PRV infection, and has no significant cytotoxicity; the polypeptide P2 can be used for remarkably down-regulating PRV UL42 protein expression and gB mRNA (messenger Ribonucleic Acid) level; based on the conservative property of Nectin-1 in a herpes virus invasion mechanism, the polypeptide P2 can also be used for inhibiting infection of other herpes viruses (such as HSV-1 and HSV-2), and an important strategy is provided for developing novel anti-herpes virus drugs.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

The invention relates to a novel crystal form of perralevir, a pharmaceutical composition containing the crystal form, a preparation method of the crystal form, application of the crystal form in medicines and application of the crystal form in treatment of herpes viruses.